Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus, ...

The other, the Federal Trade Commission, is already conducting a major investigation of pharmacy benefit managers and is suing over their pricing practices regarding insulin. She was speaking just ...

Nearly one-third of those patients were paying $35 or far more per month in 2019, according to the latest available data from ...

Drugmakers blame middlemen known as pharmacy benefit managers for high drug prices. PBMs negotiate drug prices and rebates ...

By taking steps to hold middlemen ... Affordable Insulin Now Act moves towards the US Senate. Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi ...

The price of insulin has been a major flashpoint ... Drugmakers blame middlemen known as pharmacy benefit managers for high ...

Kamala Harris and Donald Trump are both pledging to make health care more affordable in the U.S., but have largely different ...

INSULIN LITIGATION DEEP-DIVE — As Congress ... in a New Jersey district court against the three major pharmacy middlemen — CVS Caremark, Express Scripts and OptumRx — and three insulin ...

No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...

One exception that enjoys bipartisan support, however, is the effort to rehab the drug supply chain. It’s currently dominated ...

“I’ll lower the cost of insulin and ... from the middlemen who operate between Big Pharma and the insurance companies who use opaque practices to raise your drug prices and profit off your ...

The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...